Bright Minds Biosciences (DRUG) Stock Price, News & Analysis

Company Overview

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Key Stats

• Today's Range: $35.95 to $37.06
• 50-Day Range: $29.86 to $46.29
• 52-Week Range: $0.93 to $79.02
• Volume: 5,757 shs
• Average Volume: 81,743 shs
• Market Capitalization: $252.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $84.33
• Consensus Rating: Buy

Bright Minds Biosciences Stock Analysis - MarketRank™

Bright Minds Biosciences scored higher than 85% of companies evaluated by MarketBeat, and ranked 172nd out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Bright Minds Biosciences has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bright Minds Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($1.33) to ($3.83) per share.

Price to Book Value per Share Ratio

Bright Minds Biosciences has a P/B Ratio of 6.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.70% of the float of Bright Minds Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Bright Minds Biosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bright Minds Biosciences has recently decreased by 19.94%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bright Minds Biosciences does not currently pay a dividend.

Dividend Growth

Bright Minds Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.70% of the float of Bright Minds Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Bright Minds Biosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bright Minds Biosciences has recently decreased by 19.94%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.36

News Sentiment

Bright Minds Biosciences has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Bright Minds Biosciences this week, compared to 2 articles on an average week.

Search Interest

12 people have searched for DRUG on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

6 people have added Bright Minds Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bright Minds Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DRUG Stock Analysis - Frequently Asked Questions

How have DRUG shares performed this year?

Bright Minds Biosciences' stock was trading at $36.02 at the start of the year. Since then, DRUG stock has increased by 0.4% and is now trading at $36.15.
View the best growth stocks for 2025 here.

How were Bright Minds Biosciences' earnings last quarter?

Bright Minds Biosciences Inc. (NASDAQ:DRUG) issued its quarterly earnings results on Thursday, February, 13th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.24.

When did Bright Minds Biosciences' stock split?

Shares of Bright Minds Biosciences reverse split before market open on Friday, July 14th 2023. The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Who are Bright Minds Biosciences' major shareholders?

Bright Minds Biosciences' top institutional shareholders include Janus Henderson Group PLC (11.48%), RA Capital Management L.P. (10.40%), Vivo Capital LLC (5.68%) and Point72 Asset Management L.P. (3.05%).
View institutional ownership trends.

How do I buy shares of Bright Minds Biosciences?

Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bright Minds Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include HubSpot (HUBS), Blink Charging (BLNK), ConocoPhillips (COP), Netflix (NFLX), ForgeRock (FORG) and SoFi Technologies (SOFI).

Company Calendar

• Last Earnings: 2/13/2025
• Today: 2/20/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DRUG
• CUSIP: N/A
• CIK: 1827401
• Web: brightmindsbio.com
• Phone: 64-7407-2515
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $84.33
• High Stock Price Target: $93.00
• Low Stock Price Target: $75.00
• Potential Upside/Downside: +133.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-2,060,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -18.60%
• Return on Assets: -17.03%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 11.31
• Quick Ratio: 11.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.92 per share
• Price / Book: 39.29

Miscellaneous

• Outstanding Shares: 7,040,000
• Free Float: 4,039,000
• Market Cap: $254.50 million
• Optionable: Not Optionable
• Beta: -6.71